http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#Head http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#provenance http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#pubinfo http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion http://purl.obolibrary.org/obo/DOID_1040 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1040 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB11581 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association http://www.w3.org/2000/01/rdf-schema#label venclexta is a bcl 2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll 1 1 in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy 1 2 venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll venclexta is indicated in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy this indication is approved under accelerated approval based on response rates see clinical studies 14 2 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB11581 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#provenance http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#pubinfo http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig http://purl.org/nanopub/x/hasSignature UEAodeV68hw8mC0CA6OgsSqxZQZRTXb+6gmGO9dfLB1kL/GQiP7A1d/m92QNaUFzkYSGce7Llgcsk7J0QfDGuiPTljXHtd1J/T3Uvy4ALnnPOI3F4qj6zEXjVBhIFIlNGX7XFZqsncHHvXkTHl3mzmvoirZMuelsfM8rUEgyhHQ= http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://purl.org/dc/terms/created 2021-06-12T12:28:30.662+02:00 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs